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ABSTRACT
Objectives: To estimate the impact of drotrecogin alfa (DA)
on intensive care workload in an observational study while
illustrating the use of propensity score (PS) matching to
control for recruitment bias.
Methods: PREMISS is a prospective, multicenter pre–post
study. Its goal was to evaluate DA in the treatment of severe
sepsis with multiple organ failure. Inclusions took place
before (control patients) and after (DA-treated patients) the
drug’s market authorization. Workload was measured in
euros using the French classiﬁcation of medical procedures. It
was compared between the groups via random effects gamma
regression using two techniques: 1) regression adjusting for
the patients’ initial characteristics on the whole population;
and 2) PS matching. A structural equation model was used to
explore the pathways leading to a workload increase.
Results: Drotrecogin alfa is estimated to increase intensive
care unit (ICU) workload by 20% (P = 0.045) according to
the multivariate model and 34% (P = 0.002) according to
the PS-matched one. In the structural equation model ﬁtted,
only DA’s direct effect on the occurrence of bleeding events
reaches signiﬁcance (P = 0.024).
Conclusions: We found a signiﬁcant effect of DA on ICU
workload with both standard methods of adjustment and PS
matching. This effect appears to be mainly due to DA’s effect
on bleeding events. The analysis illustrated the usefulness of
PS methods in the analysis of observational data, as it leads to
conclusions similar to the traditional multivariate regression
approaches while avoiding making too many adjustments,
allowing focusing on the treatment effect.
Keywords: drotrecogin alfa, gamma regression, intensive
care, observational studies, propensity score, random effects,
workload.
Introduction
There has been considerable debate on the role of
observational studies for the evaluation of an inter-
vention’s effect. Many researchers claim that nonran-
domized studies lead to unreliable results and appeal
for the exclusive use of randomized clinical trials
(RCTs) [1]. The latter are considered the “gold stan-
dard” because they imply the equality of the distribu-
tion of the variables measurable at the time of
randomization [2]. On the contrary, nonrandomized
studies cannot guarantee that the populations being
compared share the same distribution of prognostic
factors. When the populations differ in some baseline
characteristic predictive of the outcome of interest,
the estimation of the intervention effect can be biased.
We will use the term of recruitment bias (a particular
case of selection bias) to refer to these situations.
Despite the risk of producing biased treatment effect
estimates, some authors advocate the use of nonran-
domized studies on the basis that, when correctly
conducted, they can lead to results similar to those
reported in RCTs [3]. There are indeed some argu-
ments in favor of nonrandomized studies. First of all,
even if their results are prone to more skepticism than
those arising from RCTs, there are some situations
where randomization is infeasible (which is some-
times the case in the ﬁeld of surgery or living habits),
not ethical (for example, if the efﬁcacy of the inter-
vention is already acknowledged) or simply too costly.
In a recent review of the question, the NHS (United
Kingdom’s National Health Service) concluded that
nonrandomized studies should be used only in these
cases [4]. There are however, more possible advan-
tages to nonrandomization. First, some sources of
already available observational data can provide
valuable information. Moreover, RCTs tend to be
conducted under strict protocol-driven conditions,
different from what will be the use of the intervention
in real practice. Some authors assert that randomized
studies do not provide much information relevant
to decision-makers [5]. Thus, although most clinical
researchers see observational studies as exploratory
tools whose results need to be conﬁrmed by RCTs,
nonrandomized studies can also be carried after an
RCT to assess the external validity of the ﬁndings.
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The PREMISS study is an example of such an appli-
cation. It is a study founded by the French ministry
of health in 2002 to estimate drotrecogin alfa (DA)’s
impact in intensive care practice, in cooperation
between the two professional associations of intensive
care practitioners in France: the SFAR (French Society
of Anesthesia and Intensive Care) and the SRLF
(French Speaking Reanimation Society).
Sepsis is a systemic inﬂammatory response to infec-
tion, causing widespread activation of inﬂammation
and coagulation pathways. Severe sepsis (organ dys-
function and perfusion abnormalities) or septic shock
affect broadly 15% of French intensive care patients
and are associated with high mortality rates (35% at
30 days in 2001) [6]. DA is a recombinant version of
human activated protein C, a coagulation factor that
as been shown to reduce severe sepsis mortality by
20% [7]. It is indicated in Europe for the treatment of
adult severe sepsis with multiple organ failure (MOF).
The main objective of the PREMISS study was to
estimate the observational costs of DA’s introduction
in French intensive care units (ICUs). Because DA’s
efﬁcacy had already been explored in a large multi-
center RCT, it would have been unethical to randomize
patients in a control group. Furthermore, some other
features of an RCT, like the blinded allocation of treat-
ments or the highly protocoled patterns of care, would
have been incompatible with the study’s observational
objectives. For instance, because DA is known to
increase the probability of hemorrhagic events, car-
egivers aware of the treatment received by their patient
may monitor more severely those being administered
this product. The PREMISS design was therefore con-
ducted without randomization.
To account for the likely presence of confounding
in the PREMISS study, we used the propensity score
[8] (PS), an increasingly used method to deal with re-
cruitment bias. It will be illustrated in the estimation
of DA’s impact on intensive care workload. This
impact will subsequently be explored using structural
equation modeling [9]. The drugs’ “theoretical” (i.e.,
according to the RCT results) [10] and observational
cost-effectiveness [11] have been assessed elsewhere.
Methods
The PREMISS Study
The intervention to be evaluated is the administration
of DA at the recommended dosage of 24 mg/kg/h for
96 hours (the physicians were free to use different pro-
tocols). The inclusion criteria are those deﬁned in
the European indications for DA: adult patients (in
practice, 13 patients less than 18 years old at their
admission were included and kept for analysis. All
were more than 15 years old) with severe sepsis with
MOF and without contraindications (active internal
bleeding, intracranial pathology, neoplasm or evidence
of cerebral herniation, concurrent heparin therapy
15 International Units/kg/h, known bleeding diathe-
sis except for acute coagulopathy related to sepsis,
chronic severe hepatic disease, platelet count
<30,000 ¥ 106/L, even if the platelet count is increased
after transfusions, patients at increased risk for bleed-
ing). The PREMISS study follows a quasi-experimental
pre–post design. In a “before” phase, from September
2002 to January 2003, before DA’s marketing autho-
rization, patients were included in a control group.
The “after” phase was carried from January 2003 to
December 2004, once DA was available. Among the
patients eligible for DA treatment, those actually
receiving the drug were included in the study. As phy-
sicians were not compelled to treat with DA every
patient fulﬁllling the drug’s indication, as they would
have been in a clinical trial setting, the study design
does not exclude the presence of recruitment bias. The
“after” phase lasted longer to include roughly the same
number of patients than in the “before” phase (as all
patients potentially eligible for DA before it was avail-
able were included in this phase). This longer inclusion
phase does not affect the length of follow-up (mortality
is assessed at 28 days). Analyses were conducted in an
intention to treat fashion: all the patients in the “after”
phase were considered as treated with DA, even if they
did not conform to DA’s recommended dosage or if
DA infusion was stopped before the 96-hour period.
Patients were followed up until their discharge from
the hospital.
Data Collection
Use of an Internet database. Information was col-
lected in a decentralized fashion using an online case
report form (eCRF). The information was then cen-
tralized in a protected server in a single database. The
choice of an Internet questionnaire allowed for the
inclusion and noninclusion criteria to be automatically
validated. The data are checked as they are entered,
which substantially reduces the number of errors
and queries. Quality controls of the information sub-
mitted were also automated, making easier the data-
monitoring process. Conﬁdentiality of the data was
ensured by the use of unique password-protected iden-
tiﬁers for each participating ward and by the anony-
mization of patients by an alphanumeric code. The
eCRF, its interface, and all associated software were
conceived, programmed, and maintained by the
authors in cooperation with the intensive care practi-
tioners’ societies. We consequently were in possession
of a tool entirely customizable to the research needs.
The data collected included information about: the
ICU itself; the patients’ characteristics at the time of
their admission on the ward; their severity at the time
of inclusion; the administration of antibiotics, corti-
coids, DA (in the “after” phase), and other drugs;
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hemorrhagic and transfusion events; the procedures of
care given during their stay on the ICU; their survival
status at discharge from the ICU, from the hospital,
and 28 days after sepsis initiation.
Initial characteristics. As treatment allocation was
not randomized, we needed to take multiple sources of
bias into account. We tried to gather as many data as
possible on the patients’ initial characteristics. They
were measured at ICU admission or at enrollment in
the study. These included demographic variables (age,
gender, weight, prior location, reason for ICU admis-
sion), medical conditions (McCabe score, chronic renal
failure, chronic liver disease, congestive cardiomyo-
pathy, COPD, diabetes mellitus, immunosuppressive
treatment, chemotherapy, metastatic cancer, hemato-
logical malignancies, HIV, corticotherapy for more
than 3 weeks), infection sites (lung, intraabdominal,
urinary tract, central nervous system, etc.), the biologi-
cal variables used in the SAPS II [12] and LODS [13]
scores, and disease severity variables (SAPS II on admis-
sion, septic shock at enrollment). On the whole, 46
initial characteristicswheremeasured and considered in
the analysis.
Workload measures. The measure of workload used
is based on the new French classiﬁcation of medical
procedures, which comprises more than 7000 techni-
cal acts. Each is arranged hierarchically according
to the material and human resources necessary for
its realization. A reimbursement rate linked to the
resources (economic or not) required is associated
with each act.
The use of this classiﬁcation in intensive care was
troublesome: because severe sepsis is only a syndrome,
the range of all potential interventions occurring
during a patient’s stay is quite important. Only the
most important acts were included in the PREMISS
eCRF: essentially, those relative to organ support or
monitoring (respiratory, cardiovascular, digestive,
renal, hematological, nervous system), those relative
to medical imagery (ultrasonography, tomography,
magnetic resonance image, endoscopy), and, of course,
those related with hemorrhage management. In total,
115 different technical acts were included in the eCRF.
The ICU workload is estimated as the sum of the
number of technical acts multiplied by their reimburse-
ment rate. We use the values from version 10 of the
classiﬁcation. Although this classiﬁcation serves as the
reimbursement classiﬁcation for private clinics and is
measured in euros, it should be considered a workload
measure (as the former Omega system) and not as a
cost. Reimbursement in French public ICUs is based on
the presence of some of these technical acts, and not on
their values.
Statistical analysis
Model speciﬁcation. In econometrics, it is well-known
that resource use variables can be particularly skewed.
Even if the normality of the explained variable is not a
condition of validity of the linear regression model, it
can lead to the violation of the hypothesis of normally
distributed residuals. There has been large debate over
the most appropriate way to deal with such concerns
[14,15]. We will ﬁrst use a classical linear model. If its
validity conditions are violated, we will use a general-
ized linear model (GLM) such as the Gamma model. If
we note yi the dependent variable for patient i and xi
the vector of his observed covariates, this model is
given by:
Log , and therefore expE y x x E y x xi i i i i i[ ]( ) = ′ [ ] = ′( )β β: .
The gamma distribution further implies that the
variance of the variable is proportional to the square of
the mean: V[yi|xi] = F (E[yi|xi])2, where F is the disper-
sion parameter. We use the procedure described by
Manning and Mullahy [16] to select the model to be
used.
Adjustments for Recruitment Bias
Identiﬁcation of unbalanced initial characteristics. To
explore the comparability of the “before” and “after”
groups, we computed standardized differences. They
are a quantitative measure of bias [16,17]. A standard-
ized difference is related to the degree of unbalance in
a variable means accounting for its degree of variation.
The standardized difference of a variable i is deﬁned as:
d x x s si ci ti ci ti= ∗ −( ) +( )100 22 2
Where xci and xti are the control and treatment
sample means of the ith variable and sci2 and sti2 are the
corresponding sample variances. For binary variables,
the sample means are the sample proportions. For
polychotomous variables, we compute a standardized
difference contrasting each category with all the others
and we retain the highest one. We will consider a
variable as balanced between the groups when its
absolute value of standardized difference is inferior to
10% [18].
Adjusting for recruitment bias using multivariate
regression. Multivariate regression models are the
most frequently used methods to assess an intervention
effect on a quantitative outcome variable. The model
will include an indicator of the PREMISS study phase
(“before” or “after”) as a covariate as well as the
variables for which we wish to adjust for. Some prob-
lems arise in this model. First of all, any parametric
model is more or less robust to violations of its validity
assumptions. A misspeciﬁed model can lead to errone-
ous conclusions. Furthermore, the model results will
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depend on the way the relationship between the vari-
able and the outcome is speciﬁed. For example, the
association between age and workload can be linear or
quadratic. Including age as a quantitative variable or as
a qualitative one (e.g., by quartiles) might inﬂuence the
results. Finally, when controlling for too many covari-
ates, more problems are encountered. The sample size
may be too small to accurately estimate all model
parameters, and multicolinearity issues can arise.
Adjusting for recruitment bias using PS matching
methods. An alternative to multiple covariate adjust-
ments is to select a sample of patients comparable in
each treatment group. This sample can be obtained
with a PS approach. The PS is deﬁned as the condi-
tional probability of belonging to the “after” group
given the initial covariates measured [18]. This prob-
ability replaces a large number of covariates by a single
scalar. The PS can then be used as a stratiﬁcation
variable, as a matching variable or as an adjustment
variable in a multivariate regression (or any combina-
tion of the three). Although the computation of the PS
often uses multivariate regression models, studies have
shown that the PS has the advantage of not being too
sensitive to assumptions about the functional form of
the association of a covariate with the outcome (e.g.,
linear, quadratic, etc.) [19].
Because there were missing values among the 46
initial covariates, multiple imputation procedures were
used [20,21]. We generated 10 imputed data sets, esti-
mated the PS for each and computed each patient PS as
the mean of the 10 imputation-based PS estimates.
The PS was estimated using a logistic regression
model including all 46 covariates.
Once the PS were estimated for each patient, “after”
patients were matched to “before” ones on the basis
of their PS using an optimal matching algorithm (the
optimality criteria were to minimize the distance
between the matched groups. For each pair of matched
patients, the absolute value of the difference between
their PSs was used as a distance measure). We used
Bergstralh and Kosanke’s SAS “match” macro [22].
The remaining analyseswere performed on thematched
sample adjusting only for the treatment group.
Accounting for the Clustering of Patients within the
Participating ICUs
PREMISS was a multicenter study. One of the other
conditions of validity of the linear regression model is
that the residuals are independent and identically dis-
tributed (iid). Because some patients share the same
ICU, we can expect them to be submitted to similar
unobserved treatment procedures. Their outcomes are
likely to be correlated. In consequence, so will be the
residuals of patients from the same ICU and the iid
assumption will not be met. We will use random effects
models to take into account the clustering of patients
among ICUs. In the traditional multiple regression
linear model, the outcome yij observed for patient i
from ICU j can be written as:
y x eij k ijk k ij= +∑ β
where xijk represents the kth variable observed for
patient i from ICU j, bk is the estimated effect of the kth
variable on the outcome, and eij is the error assumed to
be iid and with null expectation. This model is called
the ﬁxed effects model.
The simplest form of a random effects model is the
random intercept model, which adds a residual cluster
effect:
y x u eij k ijk k j ij= + +∑ β
The cluster effect uj is also assumed to have a null
expectation. More complex models can be speciﬁed
when adding random components to the model
coefﬁcients.
Random effects models (also called hierarchical or
multilevel models) have the advantage of providing a
correct modeling of the variation: when ﬁtting ﬁxed
effects models to hierarchically structured data, the
estimated standard errors associated with the model
coefﬁcients will be too small, leading to the overesti-
mation of the signiﬁcance of the estimates [23].
We will use a penalized quasi-likelihood approach
[24] to estimate the random effects. All models were
ﬁtted using the R statistical programming language
[25].
Further Exploration of DA’s Effect on Workload through
Structural Equation Modeling
The regression model tests DA’s effect on ICU work-
load as a whole. We tried to explore the path from
treatment phase to ICU workload using structural
equation modeling. These models use multivariate
analysis to test causal relationships between variables
in a path diagram.
There are several ways for DA’s to affect ICU
workload:
• Drotrecogin alfa could inﬂuence ICU workload
through its effect on ICU mortality: patients not
surviving ICU hospitalization are known to gen-
erate more costs (and therefore more care proce-
dures) [26]. On the other hand, surviving patients
have a higher ICU length of stay (LOS), and we
expect the LOS to be correlated with workload.
• Drotrecogin alfa is associated with adverse events,
hemorrhages in particular [7]. The occurrence of
an adverse event is expected to lead to additional
care and therefore to increase ICU workload.
Adverse events could also increase the patients’
LOS or mortality.
• Finally, DA could directly inﬂuence workload; if
DA-treated patients are more monitored.
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The interpretation of this model should be made
with caution, as two of its endogenous variables (treat-
ment phase and ICU mortality) are binary and the
others (the number of bleeding events per patient and
ICU LOS) have particular distributional shapes (the
ﬁrst is a counting event, and the second is particularly
skewed).
These alternative pathways are presented in
Figure 1. An arrow represents a speciﬁc path from one
variable to another.
The model was ﬁt using SAS (SAS, Cary, NC) pro-
cedure “proc calis,” using its default maximum likeli-
hood estimation method. The model was assessed via a
c2 goodness of ﬁt test, a nonsigniﬁcant P-value indi-
cating no differences between the model structure and
the observed data. We used the Root Mean Square
Error of Approximation (RMSEA) as a secondary
model ﬁt indicator (an RMSEA of 0.05 or less indi-
cates a good model ﬁt, an RMSEA of more than 0.10
indicates a poor model ﬁt). The individual regression
coefﬁcients were tested using t ratios.
Results
Baseline Characteristics
Once the database was checked for quality, 1096
patients were retained in the analysis: 509 and 587 in
the “before” and “after” groups, respectively. These
patients are nested within 85 different participating
ICUs and 64 different hospitals, including 49 teaching
hospitals. The proportion of medical, chirurgical, and
general ICUs is broadly balanced. The mean age of the
patients was of 60.8 years (range: 15.6–94.8). In total,
62% of the patients were of male sex. A total of 40%
of the patients were admitted in the ICU after an
internal transfer, 28% entered the ICU from an emer-
gency department, 23% after an external transfer. The
remainder entered the ICU directly. In total, 72% of
the patients are medical ones. A total of 22% of the
patients presented a McCabe and Jackson severity of
illness score of 2 (ultimately fatal disease), 6% a score
of 3 (fatal disease). The mean SAPS II severity score
at the time of admission was of 56.6 (range: 7–131).
Due to the speciﬁcity of the inclusion criteria (presence
of MOF), comparisons with other epidemiological
studies [6,26] or RCTs [7], typically focusing on severe
sepsis with or without MOF, are difﬁcult. Keeping this
limitation in mind, the population recruited in the
PREMISS study, compared to other French popula-
tions, appears to be similar in terms of admission
categories, age or sex. The severity scores are, however,
slightly higher in our population, which is not surpris-
ing because only patients with MOF were recruited.
Assessment of Recruitment Bias
Among the 46 measured initial covariates, 20 have a
standardized difference superior to 10% in absolute
value. As expected, there is strong evidence of recruit-
ment bias in the PREMISS study. The ﬁrst 10 unbal-
anced covariates are, in decreasing order of unbalance,
age (“after” patients are younger), the PaO2/FiO2
(a measure of hypoxemia) ratio (“after” patients
are more frequently ventilated), the McCabe score
(“after” patients are less severe), the Glasgow coma
score (“after” patients are less severe), the delay
between hospital admission and ICU admission
(shorter for “after” patients), the presence of a neuro-
logical infection site (more frequent among “after”
patients), urine output (values between 0.75 and
1 L/24 h are less frequent among “after” patients),
bilirubin (extreme values are less frequent among
“after” patients), the presence of an endo-
cardiovascular infection site (less frequent among
“after” patients), and the heart rate (extreme low
values—<30 bpm—are less frequent among “after”
patients). Nevertheless, patient severity did not differ
between the groups, at ICU admission (SAPS II of
56.93 vs. 56.24 in the “after” group, P = 0.54) and at
the date of severe sepsis with MOF diagnosis (LODS
of 8.62 vs. 8.90, P = 0.19). These initial characteristics
have been described in more detail elsewhere [11].
Treatment with DA ICU Workload
Bleeding Events
Lenght of Stay
Death in ICU
Figure 1 Model of drotrecogin (DA) treat-
ment, intensive care unit (ICU) survival, bleed-
ing events and ICU length of stay’s effect on
ICU workload. DA, drotrecogin alfa.
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Workload and DA Treatment Cost Estimation
Sixteen patients have a null workload. They stayed
between 2 and 7 days in the ICU and left it alive. The
distribution of the workload (Fig. 2) is clearly skewed
(skewness of 3) and does not ﬁt a normal distribution
(P < 0.0001, Shapiro-Wilk normality test). Patients in
the “after” group appear to have higher workload
measures (Fig. 3).
Among the “after” treatment group, the mean DA
cost was of €6668 (95% conﬁdence interval of 6404–
6931, for a mean patient weight of 74 kg and a cost
of €48.23 per mg of DA). Only 51% of the patients
conformed to DA’s indications of use (i.e., posology
of 24 mg/kg/h, during 96 hours unless the patient dies
before or faces an adverse effect or a treatment
contraindication). This ﬁgure illustrates the gap
between the conditions of care in RCTs and in daily
practice.
Assessment of Treatment Phase’s Impact on Workload
Model speciﬁcation. Without any covariate adjust-
ments, the linear model assessing the impact of treat-
ment phase on workload is given by:
W I= + ∗
={ }754 28 410 85. . Phase after“ ”
Where I{Phase=“after”} is the indicator variable for the
“after” treatment phase (I{Phase=“after”} = 0 if the patient
belongs to the “before” group, 1 otherwise).
Adding random effects to the intercept to control
for center effects, the model becomes:
W I= + ∗
={ }778 03 404 91. . Phase after“ ”
The random effects can be considered statistically
signiﬁcant (P < 0.0001).
As the residuals are non-normally distributed
(P < 0.0001, Shapiro-Wilk normality test), the linear
Distribution of the workload
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Figure 2 Distribution of the total workload
among the PREMISS study patients. EUR, euros.
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Figure 3 Boxplots of the total workload in the
“before” and “after” treatment groups.
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model cannot be used. Box-Cox procedures show that
a log transformation is suitable (l = 0.16).
To work on the log scale, we add a constant of 1 to
the workload to avoid null values (observed for 16
patients). Because the mean workload is of €974, this
constant can be considered negligible.
Nevertheless, even in the log-scale, the residuals
obtained from an ordinary least squares (OLS) model
(that is a linear model on the log-transformed variable)
remain heavy-tailed (kurtosis = 4.5, 95% conﬁdence
interval = [3.92–5.13]). Simulation studies have shown
that in this case, GLMs could be imprecise [16]. In the
case of a kurtosis of 4, the standard errors of the
estimates can be two times higher. Nevertheless, we
choose to use a GLM model as, despite efﬁciency losses,
they provide unbiased estimates, unlike OLS models if
there is heteroscedasticity in the log-scale error.
Using the modiﬁed Park test described in Manning
and Mullahy [16], we obtain a l parameter of 2.22
(95% conﬁdence interval of [1.61–2.83]) leading us to
use a (mixed effects) Gamma GLM.
The corresponding mixed effects gamma regression
model is given by:
W I+( ) = ( )∗ ∗( )={ }1 6 5443exp exp 0.4327 Phase after. “ ”
Without any adjustments for covariate unbalance
between the two treatment groups, DA is estimated to
increase ICU workload by 54% (exp(0.4327) = 1.54).
Treatment phase is signiﬁcant (P < 0.0001).
Full sample multivariate regression. When trying to
adjust for all of the 46 covariates used in the PS model,
the model fails to converge. To reach convergence, we
eliminate the ﬁve covariates with the lower standard-
ized differences (and therefore showing good balance
between the treatment groups) that are not associated
with workload (P > 5% in a nonparametric Mann–
Whitney test). These covariates are the presence of
an immunosuppressive treatment, diabetes mellitus,
COPD, chronic liver disease, lung infection site, and a
body temperature >39°C.
In the resulting mixed-effects Gamma GLM model,
treatment effect remains statistically signiﬁcant
(P = 0.0445), the estimated increase in ICU workload
due to DA treatment is of 20% (coefﬁcient of 0.1822).
This value, much lower than the one estimated in the
unadjusted model (53%), tends to prove that patients
recruited in the “before” phase are less severe than
patients in the “after” one. In the random intercept
model, the multiplicative effect of ICUs on baseline
workload varies from 0.52 to 3.14, indicative of some
variability in hospital practices. Nevertheless, because
the variance component due to individual variation is
of 1.0581 (on the log scale) and the one due to cluster
correlation is of 0.1858, only about 15% of the work-
load variation is due to variation between the partici-
pating ICUs.
PS matching. A total of 840 patients remain on the
PS-matched sample (77% of the initial sample). Stan-
dardized differences were calculated on this matched
sample to investigate the performance of the model.
Of the 46 covariates speciﬁed in the PS model, only
one remains above the 10% threshold: the PaO2/FiO2
ratio, describing the ventilation characteristics of the
patients. Its standardized difference between the two
treatment groups is of 10.46%. The difference is not
statistically signiﬁcant (P = 0.49, c2 test. The unbal-
ance is mostly due to a difference in the proportion of
patients actually not under ventilation, of 7% vs. 5%).
The other issue is age. On the whole, age appears to
be balanced in both groups (mean age of 63 in the
“before” vs. 63 in the “after” group, standardized
difference of 5.12%, P = 0.33). Nevertheless, if focus-
ing speciﬁcally on the patients aged 80 years or more,
the age category at higher risk according to the SAPS II
score, we ﬁnd a signiﬁcant difference (10% vs. 6% of
the patients, P = 0.04, Fisher’s exact test).
Despite these marginal differences, we can consider
that we achieve a good balance of the observed patient
characteristics in the PS-matched sample.
A mixed-effects Gamma GLM model estimated on
the matched sample including only DA treatment as
a covariate results in an estimation of this treatment’s
effect on workload increase of 34.2% (P = 0.0021).
Inclusion of the potentially unbalanced covariates
(PaO2/FiO2 ratio and age greater or equal to 80) leads
to comparable results (33.7% increase, P = 0.0024).
In the random intercept model, the baseline work-
load varies by a multiplicative constant ranging from
0.53 to 1.98. 8.8% of the workload variation is due to
variation between the participating ICUs.
The estimation results of the full sample unadjusted
and adjusted models and the matched sample model
are summarized in Table 1.
A sketch of DA’s effect on workload through struc-
tural equation modeling. All methods used here lead
to the same conclusion: DA use in the treatment of
patients with severe sepsis and MOF is associated with
an increase in ICU workload. We use a structural equa-
tion model to assess the mediating roles of ICU LOS,
ICU mortality, and hemorrhages on the relationship
between DA and ICU workload. We ﬁt the model on
the PS-matched sample to control for selection bias.
In the initial model (Fig. 1), the direct effect of
DA on ICU LOS is not statistically signiﬁcant
(P = 0.1676). As we have no reason to believe DA has
a direct effect on LOS, we remove this path from the
model. The resulting model and its estimates are pre-
sented in Figure 4.
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Two coefﬁcients fail to reach signiﬁcance. There is
no signiﬁcant association between DA treatment and
mortality, and between DA treatment and ICU work-
load. We keep this ﬁrst path in the model as DA has
been shown to decrease mortality [7]. We also keep the
second path as its P-value is close to the 5% threshold.
The goodness of ﬁt c2 indicates that there is no signiﬁ-
cant difference between the observed data and our
hypothesized model (P = 0.1678). The RMSEA crite-
rion, of 0.0329, indicates a good ﬁt.
Discussion
The PREMISS study is illustrative of the role of obser-
vational studies in medico-economic research. Its
objectives were different from those of an RCT: the
question was not to provide evidence in favor of the
efﬁcacy of an innovative treatment, but to gather infor-
mation on the impact of the introduction of this inno-
vation on a local (the French public hospitals) scale. It
is our opinion that observational studies are the best
suited for these purposes. Of course, the adoption of
a nonrandomized design brings its share of method-
ological issues. Nevertheless, a careful and rigorous
analysis can lead to adequate estimates. We developed
a PS approach to cope with nonrandomization. There
are other methods available [27], and traditional mul-
tivariate regression methods can also perform well in
the reduction of recruitment bias [28]. Nevertheless,
the PS methods are easy to implement and force the
analysts to explicitly focus on the recruitment biases.
Moreover, the use of PS matching can lead to simpler
models. Our analysis of the relationship between DA
and ICU workload is illustrative of the strengths and
weaknesses of the PS approach. An (inappropriate)
crude analysis on the unmatched sample, without
adjustments, leads to the conclusion that DA increases
ICU workload by 54%. On the opposite, an adjusted
analysis on the same unmatched sample leads to an
estimation of a 20% increase. Finally, a multivariate
analysis on a PS-matched sample estimates this
increase at 34%. Adjustment procedures on the
unmatched sample divide by two DA’s estimated
impact. The intermediate ﬁgure of 34% could be due
to two factors. The ﬁrst is the presence of residual
imbalance between the populations being compared,
even after PS matching. The second is due to the
matching process itself: it selects a subsample of
patients with comparable characteristics on both
groups. There is no guarantee that this subsample is
representative of the population of treated or poten-
tially treatable patients. Although alternative methods
Table 1 Random intercept models for the impact of DA on workload
Model
Full sample analysis PS-matched sample
Unadjusted (n = 1096) Adjusted (n = 854*) (n = 840)
Coefﬁcient 95% CI Coefﬁcient 95% CI Coefﬁcient 95% CI
Intercept 6.5443 (6.39–6.69) 6.6221 (5.43–7.82) 6.5798 (6.42–6.74)
Treatment 0.4327 (0.26–0.60) 0.1822 (0.01–0.36) 0.2944 (0.10–0.49)
Variances†
s 2(u) 0.1437 (0.07–0.27) 0.1858 (0.10–0.33) 0.1628 (0.08–0.32)
s 2(e) 1.7148 (1.57–1.87) 1.0581 (0.95–1.17) 1.6883 (1.23–1.37)
*A total of 242 patients omitted due to the presence of missing values.
†s2(u): estimated variance of the random effect term, s2(e): within-group error variance.
DA, drotrecogin alfa.
Treatment with DA
ICU Workload
Bleeding Events
Lenght of Stay
Death in ICU
    -0.0251 (p=0.4670) 0.1936 (p<0.0001)
0.0562 (p=0.0591)
    0.1018 (p=0.0032)
0.2708 (p<0.0001)
                     
                 
               0.3487 (p<0.0001)
    0.1860 (p<0.0001)
                     -0.1511 (p<0.0001)
0.0781 (p=0.0237)           
Figure 4 Structural equation modeling of
DA’s effect on ICU workload. DA, drotrecogin
alfa; ICU, intensive care unit.
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such as weighted PS regression modeling allow keeping
all study participants, PS matching has the advantage
of being the simplest and the most intuitive method.
What have we learned from this analysis? First of
all, the presence of a recruitment bias itself deserves
attention. The differences between the “before” and
“after” groups are a sign that DA-treated patients were
not selected on the basis of just the treatment indica-
tions (these corresponded to the study’s inclusion cri-
teria). As an example, DA-treated patients are younger.
Because DA is a relatively expensive treatment, the
physicians could have judged that DA is not cost-
effective for older patients. This observation challenges
the common view that clinicians base their treatment
decisions only on the basis of clinical efﬁcacy and
safety. This gap between the theoretical indications
and the observed treatment practices could not have
been observed in an RCT. One other interesting aspect
for decision-makers is that DA’s impact on the ICUs
will not be limited to its acquisition cost (at present,
DA’s cost is reported separately and is included in a
reimbursement to the ICU).
These conclusions are based on a carefully planned
analysis, where not only the issues due to nonrandom-
ization were considered, but also other potential
sources of bias. We dealt with recruitment bias using PS
methods, we tried to take the skewness of the workload
estimate into account by the use of gamma regression
and we accounted for the clustering of patients among
the ICUs using random effects modeling.
According to the structural equation model pre-
sented, the treatment will in particular increase the
patients’ ICU LOS, as the higher correlation estimate is
between ICU LOS and ICU workload. As expected,
most of ICU workload is driven by the duration of care
in ICU. The second most inﬂuential variable on ICU
workload is the occurrence of bleeding events. Bleed-
ing events increase ICU workload directly and also
indirectly, through an increase in ICU LOS and mor-
tality. The effect of ICU mortality on ICU workload is
less obvious: on one hand, deceased patients increase
directly the ICU workload; on the other hand, they
decrease the ICU LOS. On the whole, mortality
remains positively associated with ICU workload
(0.1936 - 0.1511 * 0.3487 = 0.1409). This is in agree-
ment with other studies [26]. In conclusion, the struc-
tural model leads to the same conclusion as the
regression ones: DA increases ICU workload, mostly
through its effect on bleeding events.
Nevertheless, the interpretation of this model
should be made with caution, as two of its endogenous
variables (treatment phase and ICU mortality) are
binary and the others (the number of bleeding events
per patient and ICU LOS) have particular distribu-
tional shapes (the ﬁrst is a counting event, the second
is particularly skewed). Furthermore, we do not take
into account the clustering of patients within ICUs.
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